ALFRED RESZKA, PHD
Alfred Reszka, PhD joined Lifescience Dynamics in 2019 as Chief Business Officer. Al came with over 22 years of experience at Merck & Co., Inc., most recently serving 12 years in their Global Competitive Intelligence department. Al played a pivotal role in building and developing a world-class global competitive intelligence group with high impact on brand and corporate strategy. As an executive manager of large CI teams, Al has seen, been involved in and led hundreds of secondary and primary CI research projects, competitive simulations and strategic formulation projects. Al was also co-chair for the Pharma CI conference in the US and EU from 2017 to 2019.
Previously, Al was Executive Director and Head of Strategic Business Intelligence at Merck & Co. based in its US corporate headquarters. In this role, Al oversaw a broad portfolio of intelligence service offerings covering several therapeutic areas, corporate strategy, mergers and acquisitions, business development and licensing. In this capacity, he guided the drafting of the basic research strategy for Immuno-Oncology and support of Keytruda, contributed to the commercial launch and counter-launch strategies for brands and Merck’s Biosimilars business, and was one of few selected to inform the drafting of Merck’s 2025 corporate strategy. During his tenure, Al also led several of Merck & Co.’s special strategy projects that were successful in identifying targets for acquisitions and partnering.
Al earned his B.S. and M.S. in Microbiology and his PhD in Cell and Structural Biology at the University of Illinois, Urbana-Champaign. His research included papillomaviruses (M.S.) and cell adhesion through the integrin receptors (Ph.D.). He conducted postdoctoral research at the University of Washington, Seattle, with a focus on the interaction between the Mitogen-Activated Protein Kinases (ERKs 1 and 2) and the microtubule cytoskeleton. His earlier research as part of the Merck Research Laboratories focused on the elucidation of the mechanism of action of the nitrogen-containing bisphosphonates with a focus on alendronate, which is the active pharmaceutical ingredient of Fosamax.
Alfred is based in our Manhattan, NYC, East Coast office.